Long-acting insulin analogs versus human insulins

Diabetes Technol Ther. 2008 Oct;10(5):331-2. doi: 10.1089/dia.2008.0071.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Diabetes Mellitus, Type 1 / drug therapy*
  • Diabetes Mellitus, Type 1 / economics
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / economics
  • Dose-Response Relationship, Drug
  • Drug Costs
  • Health Care Costs
  • Humans
  • Hypoglycemic Agents / economics
  • Hypoglycemic Agents / pharmacology
  • Hypoglycemic Agents / therapeutic use
  • Insulin / analogs & derivatives*
  • Insulin / economics
  • Insulin / pharmacology
  • Insulin / therapeutic use*
  • Insulin Detemir
  • Insulin Glargine
  • Insulin, Isophane / economics
  • Insulin, Isophane / pharmacology
  • Insulin, Isophane / therapeutic use*
  • Insulin, Long-Acting
  • United States
  • United States Food and Drug Administration
  • Weight Gain / drug effects

Substances

  • Hypoglycemic Agents
  • Insulin
  • Insulin, Long-Acting
  • Insulin Glargine
  • Insulin Detemir
  • Insulin, Isophane